1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
  Report
Delayed Nasdaq Copenhagen  -  08:05 2022-06-28 am EDT
52.80 DKK   +0.76%
06/22ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023
CI
06/21VIROGATES A/S : The nonspecific prognostic biomarker suPAR successfully predicts all-cause 30-day mortality in all age groups.
PU
06/20Invitation to ViroGates' investor meeting
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Invitation to ViroGates' Q1 2022 presentation

05/03/2022 | 03:31am EDT

ViroGates A/S will publish its Interim Report for Q1 2022 on Wednesday 4 May 2022.

On Friday 6 May 2022 at 10.00 CET, the company will join a web conference hosted by Västra Hamnen Corporate Finance to present a summary of the report. The company will be represented by CEO Jakob Knudsen and CFO Mark Christian Hvidberg da Silva. After their presentation, there will be a Q&A session. The conference will be held in English. You can join the conference by computer or mobile devices.

The number of participants is limited and we recommend signing up early in order to secure a spot. Please register via the following link:

https://attendee.gotowebinar.com/register/3913377810180344079

A recording of the web conference will afterwards be made available via ViroGates’ homepage www.virogates.com and Västra Hamnen Corporate Finance’s YouTube channel.

© Modular Finance, source Nordic Press Releases

All news about VIROGATES A/S
06/22ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023
CI
06/21VIROGATES A/S : The nonspecific prognostic biomarker suPAR successfully predicts all-cause..
PU
06/20Invitation to ViroGates' investor meeting
AQ
06/15ViroGates announces an offering of new shares with pre-emptive rights for existing shar..
AQ
06/15VIROGATES A/S : SuPAR as a Prognostic Marker of Ugandan Children at Risk of Severe and Fat..
PU
05/30ViroGates announces the election of Patrik Dahlen as its new chairman of the board
AQ
05/30ViroGates A/S Announces Board Changes
CI
05/25ViroGates announces the CE-IVD accreditation of its finger-prick blood-testing product,..
AQ
05/25ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product,..
CI
05/10VIROGATES : Healthy growth
AQ
More news
Financials
Sales 2021 7,66 M 1,09 M 1,09 M
Net income 2021 -17,7 M -2,52 M -2,52 M
Net cash 2021 14,9 M 2,12 M 2,12 M
P/E ratio 2021 -25,7x
Yield 2021 -
Capitalization 166 M 23,7 M 23,7 M
EV / Sales 2020 41,3x
EV / Sales 2021 57,6x
Nbr of Employees 14
Free-Float 52,3%
Chart VIROGATES A/S
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
Patrik Olof Dahlén Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VIROGATES A/S-63.61%25
EXACT SCIENCES CORPORATION-41.99%7 944
GUARDANT HEALTH, INC.-53.76%4 714
BGI GENOMICS CO., LTD.-21.31%4 174
IOVANCE BIOTHERAPEUTICS, INC.-45.78%1 627
VERACYTE, INC.-44.81%1 625